Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma
Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant
Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with lp/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving temozolomide alone, radiation followed by PCV, or temozolomide together with radiation therapy followed by temozolomide is more effective in treating anaplastic glioma.
*For Eligibility information, look up the trial at NIH by clicking on the Study Number above.*
Other eligibility criteria may apply.
Other exclusion criteria may apply.
Brain Cancer; Central Nervous System (CNS); Glioma; Solid Tumors; Neoplasms; Astrocytoma
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.
If you are considering taking part in a clinical trial, talk with your SCCA team about the pros and cons. Discuss what you learn with your health care providers, family and trusted friends. See also the Patient Guide to Clinical Trials.